Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

NCT06029309 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Tafasitamab

Sponsor

Alvaro Alencar, MD

Collaborators

[object Object]
[object Object]
[object Object]